Nurix Therapeutics Q2 2024 GAAP EPS $(0.71) Misses $(0.63) Estimate, Sales $12.092M Miss $22.105M Estimate

Author: Benzinga Newsdesk | July 11, 2024 04:02pm
Nurix Therapeutics (NASDAQ:NRIX) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.63) by 12.7 percent. This is a 57.78 percent decrease over losses of $(0.45) per share from the same period last year. The company reported quarterly sales of $12.092 million which missed the analyst consensus estimate of $22.105 million by 45.30 percent. This is a 60.58 percent decrease over sales of $30.676 million the same period last year.

Posted In: NRIX